Journal
ANNALS OF ONCOLOGY
Volume 21, Issue 7, Pages 1486-1491Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdp531
Keywords
clinical trials; DLBCL; innovative treatments; NHL; prognostic models; rituximab
Categories
Funding
- Associazione Angela Serra per la Ricerca sul Cancro
Ask authors/readers for more resources
Design and methods: To evaluate International Prognostic Index (IPI) score before and after rituximab introduction and to validate the absolute lymphocyte count (ALC)/revised International Prognostic Index (R-IPI) model, we carried out a retrospective analysis on a total of 831 patients with DLBCL. Results: Our results show that IPI lost its discriminating power with the introduction of rituximab. The analysis of our second set allowed us to validate the ALC/R-IPI model. The R-IPI and ALC/R-IPI could still be used for designing clinical trials, but both have difficulty recognizing a high percentage of poor prognosis patients, though it remains an important goal of a good prognostic model considering the modest impact of salvage treatments on survival. Conclusions: A new model on the basis of significant variables in the rituximab era and built on a large database of patients treated with rituximab is urgently needed. As prognostic models are changing with the efficacy and mechanisms of action of treatment utilized, looking for a new prognostic score is a never-ending story in which researchers are trying to hit a continuously moving target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available